Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. - Wikidata - awgldk - TriplyDB

Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.

Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.

http://www.wikidata.org/entity/Q53545742

about

PET/MRI in Oncological Imaging: State of the Art Positron Emission Tomography in Breast Cancer Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis Initial characterization of a dedicated breast PET/CT scanner during human imaging PET/CT and breast cancer.Regulation of the Warburg effect in early-passage breast cancer cells.Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.Incidental Breast Lesions Identified by (18)F-FDG PET/CT: Which Clinical Variables Differentiate between Benign and Malignant Breast Lesions?Multiparametric evaluation of breast lesions using PET-MRI: initial results and future perspectives.Use of (99m)Tc-doxorubicin scintigraphy in females with breast cancer: a pilot study.Spectrum of the Breast Lesions With Increased 18F-FDG Uptake on PET/CT.Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer.18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization A new dimension of FDG-PET interpretation: assessment of tumor biology.Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis.Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.Role of imaging in neoadjuvant therapy for breast cancer.The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.Breast ultrasonography in young Asian women: analyses of BI-RADS final assessment category according to symptoms.Present and future role of FDG-PET/CT imaging in the management of breast cancer.Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors.Considering the Relationship between Quantitative Parameters and Prognostic Factors in Breast Cancer: Can Mean Standardized Uptake Value be an Alternative to Maximum Standardized Uptake Value?Invasive cribriform carcinoma of the breast: mammographic, sonographic, MRI, and 18 F-FDG PET-CT features.Diagnostic PET Imaging of Mammary Microcalcifications Using 64Cu-DOTA-Alendronate in a Rat Model of Breast Cancer.Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013.Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.68Ga-BBN-RGD PET/CT for GRPR and Integrin αvβ3 Imaging in Patients with Breast Cancer.Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer.

P2860

Q26768474-C94E11D9-36FA-4941-9285-2F40591C81D4 Q26768486-A36B8A21-CB1F-43FD-9EFC-1A07865D386E Q31064473-3060C736-C96A-40BF-A52A-7A2D70F4F298 Q33510313-221F3103-BC9E-418F-ABFD-2E737C03C8E4 Q33685937-F8BA65C0-1F4E-418B-B096-50E610193078 Q33857589-750319D0-7330-4900-9D16-0DD61A92E5CD Q34256370-57F23BB1-5D0E-4CE3-BF82-316AAA8FFE78 Q34594985-C67AA1F9-6DA5-4B3B-8CE8-BB53949FB9E9 Q35109871-4B6285C6-F2A6-49CE-8A9A-CC3180831379 Q35131272-89F2472B-41C5-4DEE-856D-113F38B38364 Q35237222-5DEDB496-CD2B-4C5C-A841-654289C0453A Q36193522-0F067101-2DDB-42D6-938C-1C67A8BC7275 Q36295637-7D886C9A-60F7-4829-A169-94956AD1F72A Q36992771-D86A8B76-1F68-44CB-8254-AA9499D7F073 Q37407235-3F04715F-BEE1-40E3-8D7B-99FBE865A137 Q37440346-8C82D0E4-7BB5-480B-B826-1B52D2AC2A1D Q37827752-FFB921CE-BFA0-4947-AE49-1A099F559D40 Q38165388-5C07D95F-AA0D-4651-A6AA-E20F9E2DC198 Q38171320-7650E364-F960-4C3A-A2F4-7D4096C956A6 Q38269204-DFA1DD91-834D-4F17-9A05-8559226ACAC4 Q38366386-DAB2A018-A050-4841-BEA6-DAC746E3FDB9 Q38411448-261F01EE-21DA-406A-B3C4-25892FDACD51 Q38446353-3F02A849-8206-4252-9B79-8E4BC354AF5A Q38462434-E7ECB124-D5C3-4D36-9E5E-3516EF65C472 Q38474926-191DA18E-65C5-41A1-A41B-93FBD27A3C51 Q38687620-231BED4B-442F-48CE-A4E5-C6FF7B2C9147 Q40785953-83E7652E-C4FE-4A72-BE20-F1FA4F5292DC Q41643948-F53FB840-89CD-4F7B-A679-7FD18C37AB78 Q42376460-F9395B51-7E97-46FD-A14B-C1FAFE113729 Q43859079-F4046AEE-686B-4DC3-9EA0-B7473174A85B Q46365253-3E0D935E-4D91-4AD9-9F2A-B89D600259C3 Q48175913-4F3E1850-1644-47FD-9606-AAE4FDCD6204 Q49843303-7617F288-CC05-44B9-9F0C-C52FA1AC09DE Q50091264-C44B183B-05AF-4F6A-8953-1D6BF6BBCD57 Q51698890-ED43D849-A2C7-459B-ACCA-38423EEA464B Q53076367-92301D31-3062-4075-8AA3-77825A05DC68 Q54545607-37EB4E2D-1706-481A-BB17-08D088B21222

P2860

Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.

http://www.wikidata.org/entity/Q53545742

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Clinicopathologic factors asso ...... -PET in primary breast cancer.

@en

Clinicopathologic factors asso ...... -PET in primary breast cancer.

@nl

type

label

Clinicopathologic factors asso ...... -PET in primary breast cancer.

@en

Clinicopathologic factors asso ...... -PET in primary breast cancer.

@nl

prefLabel

Clinicopathologic factors asso ...... -PET in primary breast cancer.

@en

Clinicopathologic factors asso ...... -PET in primary breast cancer.

@nl

P1433

Q53545742-2D9D73FA-6375-468D-A94F-A8B86FAB53A9

P1476

Q53545742-0D03414D-1126-4FF4-A34B-B1FC52C34F15

P2093

Q53545742-14134D78-C0CB-4DEA-BC67-3219B4EC83F7

Q53545742-459F10BD-DF76-4B21-A9CA-455E8F560460

Q53545742-4F22D23B-8923-4EB1-9514-6C09A987EFD4

Q53545742-BE3B711E-16AA-49F5-BA39-788FE860A3D2

Q53545742-F52A3971-D943-42FE-A764-2300D2A0CBD2

Q53545742-F8683FD2-DE97-47E5-B8F3-3708F268FCC6

P2860

Q53545742-D48237BE-D2EF-4BDA-82F0-99FB94C18784

Q53545742-E151DC5B-3D4F-4343-873F-C9553845B669

P2888

Q53545742-1F38B147-5331-4874-BDFE-41AB996B7EA9

P304

Q53545742-235DBF2A-D644-4340-BECC-58D1621E1E9A

P31

Q53545742-3386F716-6BC1-4A35-B7AB-4376B688DD5B

P356

Q53545742-498C29EF-2F6B-49A6-8A8D-D4EC48F44339

P407

Q53545742-920432D1-19BF-4309-928A-B44C5B75B703

P433

Q53545742-A10874BE-23B3-4461-9530-1DC0EB301F9A

P478

Q53545742-708DF3A9-7C53-419B-8174-5554BD3C9764

P577

Q53545742-7B936DD3-FB5E-4F80-9772-22C744F9C252

P698

Q53545742-D81970EA-D422-4628-9047-A8F5ABF0875D

P356

S10549-006-9159-2

P1433

Breast Cancer Research and Treatment

P1476

Clinicopathologic factors asso ...... -PET in primary breast cancer.

@en

P2093

Abass Alavi

http://www.w3.org/2001/XMLSchema#string

Anil Chauhan

http://www.w3.org/2001/XMLSchema#string

Hongming Zhuang

http://www.w3.org/2001/XMLSchema#string

Mitchell Schnall

http://www.w3.org/2001/XMLSchema#string

Prem Chandra

http://www.w3.org/2001/XMLSchema#string

Rakesh Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Sensitivity and specificity of first screen mammography in the Canadian National Breast Screening Study: a preliminary report from five centers.

Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

P2888

s10549-006-9159-2

P304

267-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-006-9159-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16555126

http://www.w3.org/2001/XMLSchema#string